Search All Patents in Z-ARCHIVE-Cannabis
Patent US10753935
Issued 2020-08-25
Prognostic Method And Kits Useful In Said Method
The invention generally relates to diagnostic, prognostic, and monitoring methods and assays for breast cancer and kits that may be used in such methods. More particularly, the invention relates to a method of prognosis of a patient afflicted with breast cancer, including determining the level of HER2/CB2 heteromer expression in a biological sample obtained from the patient.
Much More than Average Length Specification
View the Patent Matrix® Diagram to Explore the Claim Relationships
USPTO Full Text Publication >
- 1. A method comprising:
providing a test sample comprising a biological sample from a subject; contacting the test sample with a HER2/CB2 heteromer binding composition comprising one or more antibodies that specifically bind to a HER2/CB2 heteromer, wherein the one or more antibodies comprise anti-HER2 antibodies, anti-CB2 antibodies, or both, or one or more antigen-binding fragments of the one or more antibodies to form a mixture; incubating the mixture for a time sufficient to permit binding; determining from the mixture a level of HER2/CB2 heteromer in the biological sample; comparing the level of HER2/CB2 heteromer in the biological sample to a standard level of HER2/CB2 heteromer obtained from normal or cancer-free tissue or from an archived pathology sample containing a known level of HER2/CB2 heteromer protein expression; classifying the level of HER2/CB2 heteromer in the biological sample as not detectable, low, or elevated based on the comparison; and treating the subject classified as having an elevated level of HER2/CB2 heteromer by administering a pharmaceutical agent capable of disrupting a HER2/CB2 heteromer, wherein the pharmaceutical agent capable of disrupting the HER2/CB2 heteromer is Δ9-tetrahydrocannabinol.
